Andere talen Innoviva, Inc.

Aandelen

INVA

US45781M1018

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
15,2 ^USD	-1,11%		-0,39%	-5,24%

24/04	Innoviva, Inc.'s dochteronderneming Innoviva Specialty Therapeutics, Inc.'s positieve Fase 3 gegevens van oraal zoliflodacin voor de behandeling van ongecompliceerde gonorroe aangekondigd op ESCMID Global 2024	CI
04/03	Armata Pharmaceuticals sluit $35 miljoen kredietovereenkomst af met Innoviva-eenheid	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	25/04
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	24/04
Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	29/02
Innoviva: Q4 Earnings Snapshot	29/02
Earnings Flash (INVA) INNOVIVA Reports Q4 Revenue $85.8M	29/02
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress	29/02
Innoviva, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics	06/02
Innoviva Specialty Therapeutics Appoints David Altarac, MD, as Chief Medical Officer	06/02
Innoviva Insider Sold Shares Worth $153,810, According to a Recent SEC Filing	17/11
Innoviva Specialty Therapeutics - Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	02/11
Innoviva: Q3 Earnings Snapshot	01/11
Tranche Update on Innoviva, Inc.'s Equity Buyback Plan announced on November 9, 2022.	01/11
Innoviva, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress	01/11
Earnings Flash (INVA) INNOVIVA Posts Q3 Revenue $67.3M	01/11
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea	01/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Innoviva, Inc.

Aandelen

INVA

US45781M1018

Andere talen

Filters